Search

everythinglearnresearchcommunity

for

Search:↓

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

Tretinoin may enhance minoxidil's effectiveness for those not responding to minoxidil alone, but it could reduce efficacy for some who are already responding to minoxidil. Tretinoin requires careful use, including skin moisturizing and sun protection due to increased sensitivity.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

Apply tretinoin cream first, then minoxidil, as tretinoin can enhance minoxidil absorption. Allow some time between applications to avoid skin irritation.

The conversation is about the safety of using a dermastamp at 0.25mm depth twice a day when applying Minoxidil. The user seeks confirmation on whether this practice is safe despite mixed opinions.

The user plans to use a combination of tretinoin, topical minoxidil, and topical finasteride for hair loss treatment. They seek advice on application order, timing, and tretinoin dosage.

The conversation is about the application timeline for tretinoin and minoxidil. It discusses whether to wait 30 minutes to an hour after applying tretinoin before using minoxidil or to apply tretinoin at night and minoxidil in the morning.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

User shares 2-month progress with fin, min, dermarolling. Others discuss consistency, regrowth, shedding, and potential side effects.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The user experienced hairline improvement using topical 5% Minoxidil in the first month and 8% Minoxidil with 0.3% topical finasteride in the second month, along with batana oil, Vitamin D, and biotin. The user takes two doses daily and reports a thicker, stronger hairline.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The conversation is about a user's hair transplant progress using 3000 grafts with DHI technique, foam Minoxidil, Tretinoin, and Dutasteride after 5.5 months. Commenters are impressed with the results, noting significant improvement.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

A 30-year-old with diffuse thinning and a balding crown is using a treatment regimen of a 2-in-1 pill containing finasteride, minoxidil, and biotin, along with various supplements. After two weeks, no side effects have been experienced, and updates with pictures will be posted monthly.

Some people have seen hair regrowth on their hairline using tretinoin and minoxidil. Specific treatments discussed include tretinoin and minoxidil.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The user experienced another hair shed and plateau at month 5 using 6% minoxidil and 0.3% finasteride, with an itchy scalp indicating potential regrowth. They find the topical spray easy to use and saw results within two months, but caution that stopping use may lead to hair loss.

Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.

The conversation discusses the effectiveness of a new hair growth serum called HERBACLE, which claims to be the world's first, but lacks reviews and is doubted by users. One user notes that its ingredients are similar to those in The Ordinary's Multi-Peptide Serum for Hair Density.